ArticleCost effectiveness and resource allocation : C/E2026
Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
Szu-Ting Chiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.